Hepregen Corporation develops bioengineered solutions for drug development including HepatoPac™
a highly functional and stable microliver platform for predictive ADME/toxicity screening.

Events

February 15-17, 2012: 4th Annual Predictive Toxicology in London, UK: Hepregen Corporation will be exhibiting at this event. Dr. Okechukwu Ukairo, Senior Principal Scientist, ADME/Tox Services, will be speaking Thursday, February 16, 2012 at 10:45 am on "A Novel Micropatterned Hepatocyte Co-culture System for Drug Metabolism and Toxicity Studies".

March 11-15, 2012: Society of Toxicoloy Annual Meeting and ToxExpo in San Francisco, CA: Hepregen Corporation will be exhibiting at this event hosted at the Moscone Convention Center. Stop by Booth #2336. Dr. Okechukwu Ukairo, Senior Principal Scientist, ADME/Tox Services, will be speaking Monday, March 12, 2012 at 9:15 am in Room 105 on "The Use of Human HepatoPac™, an In Vitro Microliver Platform, for Predictive Toxicology ".

March 27-29, 2012: 3rd Annual World PK/PD Summit in Boston, MA: Hepregen Corporation will be a sponsor for this event hosted at the DoubleTree Suites by Hilton in Boston, MA. Hepregen will also be exhibiting.

Hepregen in the News

HEPREGEN CORPORATION AND PARTNERS PRESENT FINDINGS AT KEY RESEARCH MEETING. HepatoPac™ Liver Model is Touted for its Value to Predict Clinical Parameters of Commercially Available Drugs

President and CEO, Bonnie Fendrock, is interviewed in an article on Drug Safety in the June 2011 issue of Life Science Leader.

Hepregen Corporation Awarded Massachusetts Life Sciences Center 2011 Small Business Matching Grant. Company receives $500,000 grant; continues growth through adoption of its microliver platform, HepatoPac™, by leading biopharmaceutical companies.

Hepregen Corporation Presents Results of Liver Toxicity Study at Annual Meeting of The Society of Toxicology. Hepregen’s Microliver Platform, HepatoPac™, Provides Increased Confidence in Drug Development to Impact Patient Safety.

Hepregen Corporation Announces Commercial Launch of HepatoPac™ Microliver Platform for In Vitro ADME/Tox Applications.

Hepregen Corporation Expands Agreement with Boehringer Ingelheim for the Adoption of HepatoPac™.

Assessment by Pfizer scientists in new publication demonstrates that Hepregen's HepatoPac™ platform offers higher performance than traditional in vitro metabolism systems to predict major human in vivo metabolites.

Contract Services

Hepregen offers a range of ADME/Tox services utilizing its HepatoPac platform.

Learn More


Technology

Hepregen is developing a unique, bioengineered microliver platform as a highly functional model of the liver in vivo.